Marit Krohn

922 total citations
15 papers, 378 citations indexed

About

Marit Krohn is a scholar working on Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Marit Krohn has authored 15 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Cancer Research and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Marit Krohn's work include DNA Repair Mechanisms (3 papers), Breast Cancer Treatment Studies (3 papers) and Fungal and yeast genetics research (3 papers). Marit Krohn is often cited by papers focused on DNA Repair Mechanisms (3 papers), Breast Cancer Treatment Studies (3 papers) and Fungal and yeast genetics research (3 papers). Marit Krohn collaborates with scholars based in Norway, United States and Denmark. Marit Krohn's co-authors include Miriam R. R. Aure, Kristine Kleivi Sahlberg, Aljoscha M. Flohr, J. Bullerdiek, P. Rogalla, Gordon B. Mills, Beáta Grallert, Erik Boye, Ole Christian Lingjærde and Elin Borgen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Marit Krohn

13 papers receiving 374 citations

Peers

Countries citing papers authored by Marit Krohn

Since Specialization

Citations

This map shows the geographic impact of Marit Krohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marit Krohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marit Krohn more than expected).

Fields of papers citing papers by Marit Krohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marit Krohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marit Krohn. The network helps show where Marit Krohn may publish in the future.

Co-authorship network of co-authors of Marit Krohn

This figure shows the co-authorship network connecting the top 25 collaborators of Marit Krohn. A scholar is included among the top collaborators of Marit Krohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marit Krohn. Marit Krohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Investigating myostatin inhibition by non-coding RNAS (miRNAs and circRNAs) and monoclonal antibody SRK-015 through an in silico approach 2025 ·Next research. ·Marit Krohn, (unknown), (unknown), (unknown), (unknown)	0
2	Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 2018 ·Genome Medicine ·Elen Höglander, Silje Nord, David C. Wedge, Ole Christian Lingjærde, Laxmi Silwal‐Pandit, (unknown), Hans Kristian Moen Vollan, Thomas Fleischer, Marit Krohn, (unknown), Elin Borgen, Øystein Garred, Marit Muri Holmen, Erik Wist, Bjørn Naume, Peter Van Loo, Anne‐Lise Børresen‐Dale, Olav Engebraaten, Vessela N. Kristensen	18
3	Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes 2016 ·Cancer & Metabolism ·Tonje H. Haukaas, Leslie R. Euceda, Guro F. Giskeødegård, Santosh Lamichhane, Marit Krohn, Sandra Jernström, Miriam R. R. Aure, Ole Christian Lingjærde, Ellen Schlichting, Øystein Garred, Eldri U. Due, Gordon B. Mills, Kristine Kleivi Sahlberg, Anne‐Lise Børresen‐Dale, Tone F. Bathen	56
4	Abstract 3268: Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - a randomized phase II study 2016 ·Cancer Research ·Mads H. Haugen, Ole Christian Lingjærde, Marit Krohn, (unknown), Laxmi Silwal‐Pandit, Elin Borgen, Øystein Garred, Anne Fangberget, Marit Muri Holmen, Ellen Schlichting, Helle Kristine Skjerven, Steinar Lundgren, Erik Wist, (unknown), Gunhild M. Mælandsmo, Yiling Lu, (unknown), Gordon B. Mills, Olav Engebraaten	3
5	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer 2015 ·Genome Medicine ·Miriam R. R. Aure, Sandra Jernström, Marit Krohn, Hans Kristian Moen Vollan, Eldri U. Due, Einar Andreas Rødland, Rolf Kåresen, Prahlad T. Ram, Yiling Lu, Gordon B. Mills, Kristine Kleivi Sahlberg, Anne‐Lise Børresen‐Dale, Ole Christian Lingjærde, Vessela N. Kristensen	25
6	Abstract P4-11-14: Molecular response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva - a randomized phase II study 2015 ·Cancer Research ·Olav Engebraaten, Laxmi Silwal‐Pandit, Marit Krohn, (unknown), Silje Nord, Thomas Fleischer, (unknown), Elin Borgen, Øystein Garred, Anne Fangberget, Marit Muri Holmen, Ellen Schlichting, Helle Kristine Skjerven, Steinar Lundgren, Vessela N. Kristensen, Ole Christian Lingjærde, Erik Wist, Bjørn Naume, Anne‐Lise Børresen‐Dale	2
7	Molecular characteristics in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva— Randomized phase II study. 2015 ·Journal of Clinical Oncology ·Olav Engebraaten, Laxmi Silwal‐Pandit, (unknown), Silje Nord, Marit Krohn, Hans Kristian Moen Vollan, (unknown), Elin Borgen, Øystein Garred, Anne Fangberget, Marit Muri Holmen, Steinar Lundgren, Erik A. Wist, Ole Christian Lingjærde, Bjørn Naume, Anne‐Lise Børresen‐Dale	0
8	Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c 2014 ·British Journal of Cancer ·Marit Kveine Nygren, Christina Tekle, (unknown), Rami Mäkelä, Marit Krohn, Miriam R. R. Aure, Caroline E. Nunes‐Xavier, Merja Perälä, Trine Tramm, Jan Alsner, Jens Overgaard, J. M. Nesland, Elin Borgen, (unknown), Øystein Fodstad, Kristine Kleivi Sahlberg, Suvi‐Katri Leivonen	105
9	331: Integrative analysis reveals extensive association between microRNA expression and mRNA–protein translation 2014 ·European Journal of Cancer ·Miriam R. R. Aure, Sandra Jernström, Marit Krohn, Eldri U. Due, (unknown), A.L. Børresen-Dale, Kristine Kleivi Sahlberg, Ole Christian Lingjærde, (unknown)	1
10	Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations 2013 ·Clinical Cancer Research ·(unknown), Marit Krohn, Sergio Iadevaia, Alexandr Kristian, Gordon B. Mills, Gunhild M. Mælandsmo, Olav Engebraaten	28
11	Induction of a G ₁ -S checkpoint in fission yeast 2012 ·Proceedings of the National Academy of Sciences ·(unknown), Marit Krohn, (unknown), (unknown), Olivier Maillard, Fritz Thoma, Erik Boye, Beáta Grallert	4
12	The G1-S checkpoint in fission yeast is not a general DNA damage checkpoint 2008 ·Journal of Cell Science ·Marit Krohn, (unknown), (unknown), Beáta Grallert, Erik Boye	17
13	A novel checkpoint mechanism regulating the G1/S transition 2007 ·Genes & Development ·(unknown), (unknown), (unknown), Marit Krohn, Esben A. Nilssen, Stephen Kearsey, Beáta Grallert, Erik Boye	44
14	Variation of HMGB1 expression in breast cancer. 2002 ·PubMed ·Aljoscha M. Flohr, P. Rogalla, (unknown), (unknown), Marit Krohn, (unknown), J. Bullerdiek	67
15	Das sekretorische Mammakarzinom 1989 ·Geburtshilfe und Frauenheilkunde ·Marit Krohn, G. Trams, Gordon Brandt	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact